Stay updated on Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial
Sign up to get notified when there's something new on the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page.

Latest updates to the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added to the history, and the notice about a lapse in government funding as well as Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the record to Revision 3.4.1; the previous Revision 3.4.0 was removed. These changes are administrative and do not affect core study data, eligibility criteria, or the availability of results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check28 days agoChange DetectedThe update adds a glossary display and introduces color-coded change highlighting (green for additions, red for deletions) with the revision label updated to v3.4.0.SummaryDifference1%

- Check42 days agoChange DetectedA new revision entry v3.3.4 was added to the record history and the previous v3.3.3 entry was removed, a non-core update to the page history that does not affect the study data, status, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision entry (Revision: v3.3.3) was added to the record history, and the HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry were removed.SummaryDifference0.2%

- Check92 days agoChange DetectedFooter revision text updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page.